Company intelligence / Profile preview
Implicit Bioscience
Woolloongabba, Queensland, Australiaimplicitbioscience.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
IC14 (atibuclimab) has shown a favorable safety profile in critical care patients and ALS-MND patients treated for up to 12 months. The first ADHF patient treated at University of Virginia hospital reportedly responded well to a single dose of IC14[5].
- Therapeutic areas
- PulmonologyCardiovascularNephrologyOphthalmologyNeurology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
University of Virginia (clinical research)
Beyond the preview
Go deeper on Implicit Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Implicit Bioscience.